Skip to content
Radio Logo
PodcastsLife SciencesMolecule to Market: Inside the outsourcing space

Molecule to Market: Inside the outsourcing space

Raman Sehgal
Latest episode

293 episodes

  • Molecule to Market: Inside the outsourcing space

    Pharma Services M&A Q4 2026 roundtable

    20/11/2026 | 59 mins.
    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle, with:

     

    Sami Hawwa, Managing Director and and part of the founding team at NewVale Capital

    Sabina Ouimet-Storrs, Principal at GHO Capital Partners

    James West, Managing Director, Head of Europe at Bourne Partners

     

    Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with his guests, covering:

     

    Which assumptions about pharma services investing they got wrong, and which ones they got right

     

    The ongoing bid ask valuation gap, paused processes, and the increasingly creative ways deals are being structured

     

    Which segments remain attractive, where investors are becoming more sceptical, and how to avoid getting caught up in market fads

     

    The impact of tariffs, reshoring, potential overbuilding of capacity, and AI on investment decisions

     

    Current sentiment across the market, and how optimistic they are heading into the year ahead

     

    Sami Hawwa is a Managing Director at NewVale Capital, where he focuses on investments in the services and enabling technologies underpinning the life sciences industry. At NewVale, the investment focus spans the pharmaceutical value chain, from drug discovery and clinical development through manufacturing and commercialisation. Sami is actively involved in sourcing and executing new investments and partnering with management teams to accelerate growth, strengthen operations and build scalable, market leading businesses.

     

    Sabina Ouimet Storrs is a Principal at GHO Capital, where she co leads the firm’s efforts in the biopharma subsector. She has more than a decade of experience investing in healthcare businesses across Europe and North America.

     

    Since joining GHO in 2015, Sabina has partnered with management teams through periods of significant growth and transformation. She led two successful exits, DDC and Caprion, and currently serves on the board of Ardena. She works closely with leadership teams on strategy, value creation and growth, and particularly values the partnership side of the role.

     

    Sabina began her career at PwC before moving into private equity at Fulcrum Capital in Toronto. She holds a Bachelor of Commerce from Dalhousie University and is a Chartered Professional Accountant.

    Outside of work, she is mum to three young girls, who keep her negotiation skills sharp and her ego firmly in check.

     

    James West leads Bourne Partners’ European business, bringing 15 years of M&A experience across pharmaceutical services and products. He has worked extensively with private equity funds, their portfolio companies and independent entrepreneurs in the sector, and has spent his professional career advising these groups on global M&A transactions from both London and New York.

    Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
  • Molecule to Market: Inside the outsourcing space

    From Polish Biosimilars to Building a Biologics CDMO

    13/11/2026 | 49 mins.
    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle with Adriana Kiedzierska, CEO of Rezon Bio.

     

    Adriana Kiędzierska-Mencfeld is the CEO of Rezon Bio, where she leads the company’s strategy, operations and partnerships across biologics development and manufacturing. With more than 20 years of experience in biotechnology, she specialises in recombinant proteins, purification and biosimilars.

     

    Previously, she held senior roles at Polpharma Biologics, including COO and Site Head, where she helped support the transition to commercial scale manufacturing and contributed to FDA and EMA approvals. Adriana holds a PhD from the University of Wrocław and an Executive MBA from IMD, combining deep technical expertise with strategic leadership.

     

    Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with Adriana, covering:

    How her personal story led her into science and biologics, and onto the path of helping build a biopharma hub in Poland

    How each stage of her career taught her something different, and why CEOs should create the conditions for people to achieve more

    The importance of purpose, values and doing work that is genuinely meaningful for patients

    The journey from legacy biosimilars to bringing the first Polish manufactured biologic to the global market, and ultimately into the CDMO world

    The mindset and culture shift required when moving from an established biologics organisation to a genuinely client centric CDMO business

    How Rezon Bio is positioning itself for the future around pricing, added value, partnerships and the growing importance of dual sourcing

     

    Connect with her on LinkedIn. 

     

    Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
  • Molecule to Market: Inside the outsourcing space

    Why caring is winning in the CRO space

    06/11/2026 | 51 mins.
    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle with Kevin Jones, CEO of Aliri Bioanalysis.

     

    Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with Kevin, covering:

    His journey from working nights in the lab to leading global commercial and scientific teams

    Why flexibility, care and a consultative approach are critical differentiators for smaller specialist CROs competing against one stop shop providers

    What attracted him to Aliri Bioanalysis, and the appeal of joining a fast growing, private equity backed business, something he had not previously experienced

    How the role and perception of CROs has evolved over the last 30 years, including Kevin’s five principles for what clients value when selecting partners today

    How the market has begun to rebound after a difficult few years, and why he believes the industry is entering a new molecule renaissance

     

    Kevin Jones is CEO of Aliri Bioanalysis, a contract research organisation supporting drug developers with regulated bioanalysis and PK/TK testing. He began his career running laboratories and has spent three decades leading large, multidisciplinary scientific teams across both GMP and GLP/clinical environments.

     

    Kevin previously led Global Bioanalysis at Covance, now Labcorp, and served as Vice President and General Manager of Bioanalytical/ADME, Vaccine and Discovery Laboratories at Q² Solutions, part of IQVIA. His experience spans laboratory operations, global integration and strategic growth, with a particular focus on building service organisations that scale without compromising quality or the client experience.

     

    Connect with him on LinkedIn.

     

     

    Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
  • Molecule to Market: Inside the outsourcing space

    Takeaways from CDMO Live Americas

    30/10/2026 | 51 mins.
    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

     

    Ben Locwin, Senior VP at Reliant Life Sciences

    Jennifer Chadwick, Founder at Jennifer Chadwick Consulting LLC

    Jeff Buguliskis, Deputy Chief Editor at Outsourced Pharma

     

    Your host, Raman Sehgal, discusses the takeaways from CDMO with his guests on a live panel from Boston. The event was hosted by PharmaSource and Molecule to Market.

     

    Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
  • Molecule to Market: Inside the outsourcing space

    M2M ENCORE: Zero to a billion… A CDMO original

    23/10/2026 | 1h 49 mins.
    In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Eldered, Executive Chairman of Flerie.

    Your host, Raman Sehgal, revisits one of Molecule to Market’s most fascinating founder stories, bringing together Thomas’ original two part conversation into one episode charting the journey from a small Swedish contract manufacturer to a global CDMO powerhouse.

    Raman and Thomas discuss the pharmaceutical and biotechnology supply chain, covering:

    How a series of failed plans eventually led to the creation of a CMO before the term was widely used

    Building Recipharm from a local Swedish manufacturer into an international CDMO employing more than 9,000 people across 10 countries

    Why having cash during the financial crash created an opportunity to accelerate growth through M&A

    The decision to take Recipharm public when very few Swedish businesses, and virtually no CDMOs, were pursuing an IPO

    Why selling Recipharm after 26 years was one of the hardest decisions of his career

    How the divestment of Cobra Biologics led Thomas back into ownership, and how the gene therapy boom transformed the fortunes of the business

    Choosing passion rather than pension after his exits, and continuing to build and invest through Flerie

    The mindset, timing and calculated risk taking behind one of the most remarkable journeys in the CDMO sector

     

    Thomas Eldered co-founded Recipharm in 1995 and helped grow the company from a local Swedish contract manufacturer into one of the world’s leading CDMOs before leaving the business in 2021.

    He founded Flerie in 2011 and today serves as Executive Chairman. Flerie is a long term life science investor focused on developing companies built around scientific innovation and unmet medical needs. Thomas also serves as chairman and board member across a number of life science businesses. (Flerie)

    Thomas holds an MSc in Industrial Engineering and Management from Linköping University.

    Connect with him on LinkedIn.

     

    Molecule to Market is sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
More Life Sciences podcasts
About Molecule to Market: Inside the outsourcing space
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization. Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.   https://moleculetomarketpod.com
Podcast website

Listen to Molecule to Market: Inside the outsourcing space, Ask the Naked Scientists and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
Molecule to Market: Inside the outsourcing space: Podcasts in Family